RE:RepliCel Announces Material Patent MilestonesThings are falling into place nicely. It looks like they are tidying up some patent loose ends as they edge closer to applying for FDA approval for Dermaprecise.
From the NR:
"The new provisional patent application, filed on November 11, 2021 covers new commercial embodiments of certain technologies related to its dermal injector product portfolio which are not covered in previous patent applications."
Coincidentally November 11th was the same date Replicel sent the Dermaprecise Injector for testing at the Monasterium Laboratory.
I am looking for big things from Replicel over the next few months. My only disappointment is the lack of volume to drive the share price up as we anticipate the good news.